ESC 23: Hot Line & Late-breaking Science Video Collection

  • Published:  04 August 2023
  • Views: 

    Views Icon

    5460

  • Likes: 

    Heart Icon

    3

Up Next

ESC 23: Hot Line & Late-breaking Science Video Collection

  • Published:  04 August 2023
  • Views: 

    Views Icon

    5460

  • Likes: 

    Heart Icon

    3

Average (ratings)
No ratings
Your rating
About the episode

ESC 23 - Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss the findings from the STEP HFpEF trial.

 

Around half of patients with heart failure have heart failure with preserved ejection fraction (HFpEF), and most patients with HFpEF are overweight or obese. Patients with obesity-related HFpEF have a high burden of debilitating symptoms and physical limitations, leading to a poor quality of life. 

 

Semaglutide is a GLP-1 receptor antagonist, which has been shown to substantially produce weight loss in people who are overweight and obese. STEP HFpEF aimed to test the hypothesis that treatment with semaglutide can improve symptoms in patients with HFpEF and obesity. 592 patients were randomized to receive once-weekly semaglutide 2.4mg or placebo for 1 year. 

 

The trial met both primary endpoints, showing a mean change in body weight of -13.3% with semaglutide, and a change in KCCQ-CCS of 16.6 points from baseline to week 52.


 
Recorded on-site at ESC Congress 2023, Amsterdam. 

 

Editors: Mirjam Boros and Jordan Rance

Video Specialists: Dan Brent, Tom Green, Mike Knight, Oliver Miles

Overview

What's hot at the European Society of Cardiology (ESC) Congress 2023?

Browse our curated coverage of the latest updates in cardiology from Amsterdam.

  • Watch our View From the Thoraxcenter series for a concise line up of the most awaited trials from Prof Nicolas Van Mieghem and Dr Joost Daemen
  • For a deeper dive into key clinical trial data and its applicability, host, Dr Harriette Van Spall meets with Principal Investigators in her Late-Breaker Discussion series.
  • View a condensed summary of the crucial takeaways from each day in our Wrap-Up series with Dr Mirvat Alasnag.
  • Our short, accessible Expert Interviews with select faculty focus on data, patient care and the future of their field.
  • We will feature personal perspective in Behind the Heart series focusing on career pathways, personal motivations and perspectives on the field.

More from this programme

Part 4

Expert Interviews

25 sessions
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now

Part 6

Behind the Heart

23 sessions
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now

Faculty Biographies

Harriette Van Spall

Harriette Van Spall

Associate Professor of Medicine, Director of E-Health and Virtual Care

Dr Harriette Van Spall is an Associate Professor of Medicine and cardiologist and serves as Director of E-Health at McMaster University, Canada. She completed her medical and postgraduate clinical training at the University of Toronto and earned a Master of Public Health degree at Harvard University, US. Dr Van Spall is a Canadian Institutes of Health Research-funded clinical trialist and researcher with a focus on heart failure, health services, and health disparities.

She has garnered more than $4 million in research funding, has won several research awards, and has published her work in high-impact medical journals. She is an invited speaker, media correspondent, and editorial board member active in peer review at several high-impact medications journals and grant funding agencies, including Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada.

Dr Van Spall is an Editorial Board…

View full profile
Mikhail Kosiborod

Mikhail Kosiborod

Cardiologist

Dr Mikhail Kosiborod is a cardiologist, the Vice President of Research at Saint Luke's Health System, and Professor of Medicine at the University of Missouri-Kansas City, US.

He is also Director of Cardiometabolic Research and Co-Director of the Saint Luke’s Michael & Marlys Haverty Cardiometabolic Center of Excellence at Saint Luke's Mid America Heart Institute. Dr Kosiborod is an internationally-recognised expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes.

Dr Kosiborod is involved in the leadership of numerous clinical trials and multi-center registries, and is currently the principal investigator of several investigator-initiated, multi-center trials in diabetes and cardiovascular disease.

View full profile

Comments

You must be to comment. If you are not registered, you can register here.